Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
The steady and inexorable growth of the orphan drug market remains one of the prominent themes in the fourth edition of the “EvaluatePharma Orphan Drug Report 2017”. What has changed in the last 12 months according to the report is the increased scrutiny of the price of these lifesaving products.
“The image of the plucky small biotech striving to develop treatments for the rare diseases largely ignored by big pharma is long gone. Instead, this year we again find big pharma dominating the sector. Seven of the top 10 companies by orphan drug sales are global industry players”, said Lisa Urquhart, EP Vantage editor and report contributor. “And the pricing incentives are substantial”, added Andreas Hadjivasiliou, report author and EvaluatePharma analyst, “Of the top 100 drugs in the US the average cost per patient per year for an orphan drug was $140,443 in 2016, compared with $27,756 for a non-orphan, putting pressure on the industry to continue to generate innovations that justify the huge costs of treatments”..
EvaluatePharma Orphan Drug Report 2017 Highlights:
The, “EvaluatePharma Orphan Drug Report 2017”, based on commercial intelligence and consensus forecasts from the EvaluatePharma service can be downloaded at www.evaluategroup.com/orphandrug2017.
Evaluate provides trusted commercial intelligence for the pharmaceutical industry and their advisors.
Our EvaluatePharma Vision platform provides complete and dynamic asset valuations alongside a seamless, comprehensive view of the global market.
Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into the current and future developments in the industry.
Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com.